AlloVir, Inc. (NASDAQ:ALVR - Get Free Report) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 59,500 shares, a drop of 14.0% from the January 15th total of 69,200 shares. Currently, 2.6% of the shares of the stock are sold short. Based on an average trading volume of 26,100 shares, the days-to-cover ratio is currently 2.3 days.
AlloVir Stock Performance
Shares of NASDAQ ALVR traded down $0.58 during midday trading on Thursday, reaching $9.83. 6,267 shares of the company traded hands, compared to its average volume of 31,505. The firm has a market cap of $49.54 million, a PE ratio of -0.49 and a beta of 0.65. The stock's 50-day simple moving average is $9.98 and its 200-day simple moving average is $14.38. AlloVir has a 12 month low of $7.96 and a 12 month high of $24.15.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Gilead Sciences Inc. bought a new position in shares of AlloVir during the fourth quarter valued at $6,987,000. Jacobs Levy Equity Management Inc. bought a new position in shares of AlloVir in the fourth quarter valued at about $279,000. Tang Capital Management LLC bought a new position in shares of AlloVir in the fourth quarter valued at about $232,000. Woodline Partners LP bought a new position in shares of AlloVir in the fourth quarter valued at about $190,000. Finally, Squarepoint Ops LLC bought a new position in shares of AlloVir in the fourth quarter valued at about $142,000. 66.05% of the stock is owned by institutional investors.
About AlloVir
(
Get Free Report)
AlloVir, Inc engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Featured Stories
Before you consider AlloVir, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AlloVir wasn't on the list.
While AlloVir currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
